Inhibrx Cost Of Revenue from 2010 to 2025

INBX Stock  USD 12.95  0.61  4.50%   
Inhibrx Cost Of Revenue yearly trend continues to be fairly stable with very little volatility. Cost Of Revenue will likely drop to about 1 M in 2025. During the period from 2010 to 2025, Inhibrx Cost Of Revenue regression line of annual values had r-squared of  0.13 and arithmetic mean of  22,984,450. View All Fundamentals
 
Cost Of Revenue  
First Reported
2010-12-31
Previous Quarter
1.1 M
Current Value
M
Quarterly Volatility
19.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Inhibrx financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Inhibrx's main balance sheet or income statement drivers, such as Interest Expense of 38.4 M, Minority Interest of 0.0 or Tax Provision of 2.6 K, as well as many indicators such as Price To Sales Ratio of 940, Dividend Yield of 0.0021 or PTB Ratio of 38.9. Inhibrx financial statements analysis is a perfect complement when working with Inhibrx Valuation or Volatility modules.
  
Check out the analysis of Inhibrx Correlation against competitors.
For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.

Latest Inhibrx's Cost Of Revenue Growth Pattern

Below is the plot of the Cost Of Revenue of Inhibrx over the last few years. Cost of Revenue is found on Inhibrx income statement and represents the costs associated with goods and services Inhibrx provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities. It is Inhibrx's Cost Of Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Inhibrx's overall financial position and show how it may be relating to other accounts over time.
Cost Of Revenue10 Years Trend
Slightly volatile
   Cost Of Revenue   
       Timeline  

Inhibrx Cost Of Revenue Regression Statistics

Arithmetic Mean22,984,450
Geometric Mean12,096,223
Coefficient Of Variation83.98
Mean Deviation13,263,381
Median25,510,000
Standard Deviation19,301,497
Sample Variance372.5T
Range72.5M
R-Value(0.36)
Mean Square Error346.5T
R-Squared0.13
Significance0.17
Slope(1,472,426)
Total Sum of Squares5588.2T

Inhibrx Cost Of Revenue History

2025M
20241.1 M
20231.2 M
20222.8 M
20212.7 M
202073.5 M
201947.9 M

About Inhibrx Financial Statements

Inhibrx investors use historical fundamental indicators, such as Inhibrx's Cost Of Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Inhibrx. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Cost Of Revenue1.1 MM

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.